|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006684,
umls-concept:C0008976,
umls-concept:C0018802,
umls-concept:C0026538,
umls-concept:C0026565,
umls-concept:C0031809,
umls-concept:C0205081,
umls-concept:C0205082,
umls-concept:C0286185,
umls-concept:C0752118,
umls-concept:C1280500,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-3-8
|
|
pubmed:abstractText |
Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF) studies. Mibefradil, a new calcium antagonist that selectively blocks T-type calcium channels, has been shown to be an effective antihypertensive, antianginal, and anti-ischemic agent, and because of its different mechanism of action, it may be beneficial as adjunct therapy in CHF patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:AmmonSS,
pubmed-author:BerninkP JPJ,
pubmed-author:CaspiAA,
pubmed-author:ElkayamUU,
pubmed-author:GeltmanE MEM,
pubmed-author:GhaliJ KJK,
pubmed-author:GilesT DTD,
pubmed-author:GreenbergBB,
pubmed-author:LevineT BTB,
pubmed-author:LindbergEE,
pubmed-author:MarmorAA,
pubmed-author:McKennaW JWJ,
pubmed-author:ReisinL HLH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
22
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
758-64
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10683349-Aged,
pubmed-meshheading:10683349-Calcium Channel Blockers,
pubmed-meshheading:10683349-Calcium Channels, T-Type,
pubmed-meshheading:10683349-Double-Blind Method,
pubmed-meshheading:10683349-Exercise Test,
pubmed-meshheading:10683349-Female,
pubmed-meshheading:10683349-Heart Failure,
pubmed-meshheading:10683349-Humans,
pubmed-meshheading:10683349-Male,
pubmed-meshheading:10683349-Mibefradil,
pubmed-meshheading:10683349-Middle Aged,
pubmed-meshheading:10683349-Morbidity,
pubmed-meshheading:10683349-Mortality,
pubmed-meshheading:10683349-Physical Endurance
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.
|
|
pubmed:affiliation |
Michigan Institute for Heart Failure and Transplant Care, Botsford General Hospital, Farmington Hills 48336, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
